Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Colorado Health Reporter.
Press releases published on April 10, 2025
Aurora Dentist Dr. John K. Zalesky Featured for Expertise in Gum Disease Symptoms and Prevention
EIN Presswire
·
April 10, 2025
Highlights Early Gum Disease Symptoms and Prevention Tips AURORA, CO, UNITED STATES, April 10, 2025 /EINPresswire.com/ -- Residents of Aurora, CO wondering how to tell if they have gum disease can now turn to expert insight from Dr. John K. Zalesky, DMD …
Ascend Strengthens UKG Customer Commitment with Kevin O’Dowd's Strategic Advisory Appointment
EIN Presswire
·
April 10, 2025
Veteran UKG Leader Kevin O'Dowd Unites with Ascend to Provide Guidance and Fuel Growth BOULDER, CO, UNITED STATES, April 10, 2025 /EINPresswire.com/ -- Ascend, Inc., one of the largest exclusive UKG partners in North America and UKG’s 2024 Partner of …
SOAR HEALTH, INC. SIGNS NEW LEASE WITH BOXER PROPERTY FOR 9,450 SQ FT AT 685 CITADEL DRIVE
EIN Presswire
·
April 10, 2025
Boxer Property is proud to announce that Soar Health, Inc. has signed a new lease for 9,450 square feet of office space at 685 Citadel Drive East. COLORADO SPRINGS, CO, UNITED STATES, April 10, 2025 /EINPresswire.com/ -- Boxer Property is proud to …
Immuron Travelan® highest sales in history
GlobeNewswire
·
April 10, 2025
Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history March 2025 Quarter AUD$1.3 million up 2% on prior year March 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 …
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
GlobeNewswire
·
April 10, 2025
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on …
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 10, 2025
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of …
Passing of former Chief Executive Officer, Dr. Loressa Cole
GlobeNewswire
·
April 10, 2025
SILVER SPRING, MD, April 10, 2025 (GLOBE NEWSWIRE) -- It is with profound sadness that we share the passing of our former Chief Executive Officer, Loressa Cole, DNP, MBA, RN, NEA-BC, FAAN, FACHE. Loressa was a beloved member of the American Nurses …
Harvard Bioscience Announces CFO Transition
GlobeNewswire
·
April 10, 2025
HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation will be effective …
Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event
GlobeNewswire
·
April 10, 2025
BOSTON, MA, April 10, 2025 (GLOBE NEWSWIRE) -- Odylia Therapeutics (Odylia) a nonprofit biotechnology company dedicated to expediting drug development for rare diseases, hosted a Rare Disease Day event to foster conversations about new funding models and …
Arcutis Announces Chief Financial Officer Transition
GlobeNewswire
·
April 10, 2025
WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper, …
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
GlobeNewswire
·
April 10, 2025
Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its …
Venus Concept Announces Closing of $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
·
April 10, 2025
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at- …
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
GlobeNewswire
·
April 10, 2025
SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease …
BrightSpring Health Services, Inc. to Announce First Quarter 2025 Financial Results on May 2, 2025
GlobeNewswire
·
April 10, 2025
LOUISVILLE, Ky., April 10, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its first quarter 2025 financial results on Friday, May 2, 2025, prior to the …
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 10, 2025
DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non- …
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
GlobeNewswire
·
April 10, 2025
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that two presentations and a panel …
Folia Health Expands Its Rare Renal Disease Research with a New C3G Study to Assess Real-World Disease Impact
GlobeNewswire
·
April 10, 2025
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Folia Health launches enrollment for an innovative, at-home real-world evidence initiative for individuals with C3 glomerulopathy (C3G). Designed in partnership with C3G clinicians and patients, this study uses …
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
GlobeNewswire
·
April 10, 2025
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor …
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
GlobeNewswire
·
April 10, 2025
WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
GlobeNewswire
·
April 10, 2025
Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic programs Dr. Alan Kozikowski, internationally acclaimed pioneer in the …